Caliway Biopharmaceutical co. Ltd.
- Biotech or pharma, therapeutic R&D
Caliway Biopharmaceuticals (Caliway) is a clinical-stage biopharmaceutical company committed to breakthrough drug discovery of novel small-molecule therapeutics. Listed on the Taiwan Stock Exchange (TWSE-6919), Caliway aims to become a global leader in aesthetic medicine and therapeutic innovation across unmet medical needs.
Corporate Highlights
- Listed on TWSE (6919) in October 2024
- Achieved over USD 4 billion in market capitalization, placing Caliway among Taiwan’s Top 100 enterprises
- Included in multiple prestigious global and regional indices:
- MSCI World Small Cap Index (February, 2025)
- Fastest-ever MSCI inclusion for a Taiwanese biotech post-listing
- FTSE TWSE Taiwan Mid-Cap 100 Index (December, 2024)
- Reflects Caliway’s growth trajectory among Taiwan’s top mid-cap companies
- FTSE TWSE Taiwan Eight Industries Index
- Highlights Caliway’s leadership in biopharma and healthcare sectors
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}